Objective: To study the efficacy and safety of generic Sofobuvir and ribavirin with or without pegylated IFN.
Introduction
WHO estimates that in 2015, 71 million persons were living with HCV infection in the world, accounting for 1% of the population. HCV infection is unevenly distributed, the Eastern Mediterranean Region had the highest prevalence (2.3%) followed by the European region (1.5%) [1] . Hepatitis C virus (HCV) infection is one of the most common causes of chronic hepatitis and liver transplant worldwide [2] [3] [4] . Pakistan is one of those countries with a very high prevalence rate of hepatitis C [5] . The reported cases of HCV infection in Pakistan ranges range from 2.2-14% [6] . It is estimated that about 10 million people in Pakistan are infected with HCV with the prevalence rate 6.7 %, 5 %, 1.5 %, 1.1 % in Punjab, Sindh, Baluchistan and Khyber Pakhtunkhwa respectively [7, 8] .
For a long time, interferon has remained the mainstay of antiviral therapy for Chronic Hepatitis C virus infection. Sustained viral response (SVR) rates on IFN remained far from satisfactory and the combination did not go down well with the patients and treating physicians alike because of the number of associated side effects. Moreover, interferon remained contraindicated in advanced cirrhotic patients. The landscape changed completely with the arrival of directly acting antiviral drugs (DAA's). The DAA therapy is well tolerated and boasts excellent SVR rates. A number of DAA's namely sofosbuvir, daclatasvir, velpatasvir, grazoprevir, elbasvir, abbvie 3-D combination are now approved for used in Chronic Hepatitis C infection with and without ribavirin. The results have been excellent across all genotypes. Improvement in histology of liver and the quality of health with low risk of hepatocellular carcinoma and liver related mortality is associated with attainment of SVR [9] . SVR has also shown association with viral genotype, viral load, patient's age, BMI, race, environmental and other factors [10, 11] .
Patients who received 12 weeks treatment with the nucleotide polymerase inhibitors Sofosbuvir and combined with Ribavirin and Peg Interferon demonstrated to have higher sustained virologic response rates for genotypes 1, 2, 3, 4 and 6 in comparison with treatments that include only Peg Interferon and ribavirin [12] . Sofosbuvir is administered daily with or without meal at dosage of 400mg, and is effective against all HCV genotypes. The intracellular metabolism of Sofosbuvir generates active uridine analog of triphosphate which acts as chain terminator [13] . 
Material and Methods
This was a prospective observational multicenter study with the consumption of non-probability convenient sampling procedure. The duration of study was 1 year from January 2016 till February 2017.The study was conducted after ethics committee approval of the Gujranwala Liver foundation. The Gujranwala Liver foundation is an NGO running a specialized hepatology clinic in Gujranwala, Punjab, Pakistan. The clinic offers subsidized treatment options for poor patients and funding is also available for those who are unable to afford even the subsidized rates.
Patients of both genders aged 18 or more with detectable HCV RNA by PCR and willing for treatment were included. Exclusion criteria: co infection with HBV or HIV, CTP score > 9, known allergies to sofosbuvir or ribavirin, depressive illness not controlled on treatment, eGFR < 30 ml/min, pregnant or lactating females. The patient with undetectable viral load was categorized to achieve the objective of the treatment.
Data Analysis
All data was entered and analyzed on SPSS version 20. Frequencies and percentages were measured for the qualitative variables. Chi-square test was used to assess the difference and the P value less than or equal to 0.05 was taken as significant.
Results
Total 150 patients were selected for the study including 70(46. (Table: 2).
Discussion
The burden of viral hepatitis constitutes a public health threat in many areas of the world. In 2016, the World Health Assembly approved a global strategy to achieve elimination of this public health threat by 2030. To do this, and starting from the 2015 baseline, countries and regions need to reduce new infections (incidence) by 90 % and reduce deaths (mortality) by 65 % by 2030
[14]. To achieve this in a resource poor country like Pakistan where majority of the patients rely on out of pocket health care, the cost of treatment assumes a very crucial role.
The prime objective of the study was to study the SVR12 rate of generic sofosbuvir and ribavirin with or without pegylated interferon in real life setting.
Secondary objective was the assessment of safety including serious adverse events and discontinuation of therapy with this formulation. The latest guidelines recommend sofosbuvir in combination with velpatasvir or daclatasvir with or without ribavirin for chronic hepatitis C patients infected having genotype 3. The duration of treatment varies between 12 to 24 weeks depending upon the stage of fibrosis and previous exposure to antiviral therapy [15] .
As already mentioned velpatasvir and dacltasvir are still not approved by drug regulatory authority of Pakistan leaving sofosbuvir as the only DAA option.
Generic sofosbuvir got approval in early 2016 drastically bringing down the cost of treatment significantly. In Valence Study, where Sofosbuvir and Ribavirin was used for 24 weeks the SVR12 rates in treatment naïve non-cirrhotic patients, treatment naive cirrhotic patients, treatment experienced non-cirrhotic patients and treatment experienced cirrhotic patients were 94 %, 92 %, 87 % and 60 % respectively [16] . The Lonestar-2 trial showed improvement in SVR12 of treatment experienced genotype 3 patients with overall SVR12 of 20/24 (83 %) including 10/12 who had liver cirrhosis [17] . In Boson trial, 86 % SVR12
is reported in treatment experienced genotype 3 patients [18] . Another study presented the SVR in patients with decompensated cirrhosis among patients taking triple therapy was 88.8 % [19] . In a meta-analysis of 757 patients, in which 411 were selected for study that were having HCV infection revealed SVR rate for triple regime as 88.54% [20] .
In our study, the overall SVR 12 in 150 patients was 89. 
